<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="34">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01609790</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01969</org_study_id>
    <secondary_id>RTOG-1122</secondary_id>
    <secondary_id>CDR0000734205</secondary_id>
    <secondary_id>U10CA021661</secondary_id>
    <nct_id>NCT01609790</nct_id>
  </id_info>
  <brief_title>Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumor</brief_title>
  <official_title>Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well bevacizumab given with or without trebananib
      works in treating patients with brain tumor. Monoclonal antibody, such as bevacizumab, can
      block tumor growth in different ways. Some block the ability of tumor to grow and spread.
      Others find tumor cells and help kill them or carry tumor-killing substances to them.
      Trebananib may stop the growth of tumor cells by blocking blood flow to the tumor. It is not
      yet known whether giving bevacizumab together with trebananib is more effective than
      bevacizumab alone in treating brain tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To assess the safety and tolerability of AMG 386 (trebananib) 15 mg/kg weekly in
      combination with bevacizumab 10 mg/kg every 2 weeks (Cohort 1). (closed to accrual 10/2/12)
      II. To assess the efficacy of AMG 386 in combination with bevacizumab 10 mg/kg every 2 weeks
      compared to bevacizumab monotherapy in bevacizumab-naïve patients, as measured by 6-month
      progression-free survival (PFS6) (Cohort 2).

      SECONDARY OBJECTIVES:

      I. To further assess the toxicity profile (Cohorts 1 and 2). II. To assess feasibility of
      AMG 386 15 mg/kg weekly in combination with bevacizumab 10 mg/kg every 2 weeks (Cohort 1
      [closed to accrual 10/2/12]), as measured by the percentage of patients requiring dose
      reduction/interruption or discontinuation in the first 2 and subsequent cycles.

      III. To determine the radiographic response rate (RR), median progression-free survival
      (PFS), and OS in bevacizumab-naïve patients (Cohort 2).

      IV. To assess the efficacy of AMG 386 15 mg/kg weekly in combination with bevacizumab 10
      mg/kg every 2 weeks in patients who have progressed while on bevacizumab, as measured by
      overall survival (OS) (cross-over from placebo arm of Cohort 2).

      V. To correlate outcome to treatment with tumor genotype, expression profile, and
      circulating angiogenesis biomarkers in tumor specimens (Cohort 2).

      VI. To determine the RR, PFS6, and PFS in patients who have progressed while on bevacizumab
      therapy and receive AMG 386 in combination with bevacizumab (cross-over from placebo arm of
      Cohort 2).

      VII. To determine the serum pharmacokinetics of AMG 386.

      OUTLINE: This is a safety study (cohort 1 [closed to accrual 10/2/12]) followed by a
      randomized study (cohort 2). Patients are stratified according to age in years (&lt; 50 vs &gt;=
      50), Karnofsky performance status (70-80% vs 90-100%), and recent resection (yes vs no).

      Cohort 1: Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and trebananib
      IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence
      of disease progression or unacceptable toxicity. (closed to accrual 10/2/12)

      Cohort 2: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive bevacizumab and trebananib as in cohort 1.

      ARM II: Patients receive bevacizumab as in arm I and placebo IV over 30-60 minutes on days
      1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or
      unacceptable toxicity. Patients with disease progression may cross over to arm I.

      After completion of study treatment, patients are followed up every 2 months for 1 year,
      every 6 months for 1 year, and then annually thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT) (Cohort 1)</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Defined as a clinically significant adverse event or abnormal laboratory value assessed as unrelated to disease progression, intercurrent illness, or concomitant medications and meets any of the criteria below.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (Cohort 2)</measure>
    <time_frame>At 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-related toxicity, measured by CTCAE v. 4</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility of trebananib weekly in combination with bevacizumab every 2 weeks, measured by the percentage of patients requiring dose reduction/interruption or discontinuation in the first 2 and subsequent cycle (Cohort 1)</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic RR as measured by Revised Assessment in Neuro-Oncology (RANO) response criteria (Cohort 2)</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>From the date of randomization to the date of first progression or death or, otherwise, the last follow-up date on which the patient is reported alive, assessed up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Will be estimated using the Kaplan-Meier method and differences between treatment arms will be tested in the log rank test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) (Cohort 2)</measure>
    <time_frame>From the date of randomization to the date of death or, otherwise, the last follow-up date on which the patient is reported alive, assessed up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Estimated using the Kaplan-Meier method and differences between treatment arms will be tested in the log rank test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor genotype, expression profile, and circulating angiogenesis biomarkers (Cohort 2)</measure>
    <time_frame>Day 1 of course 1, day 1 and 8 of all subsequent courses, and up to 30 days post-treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">141</enrollment>
  <condition>Adult Anaplastic Oligodendroglioma</condition>
  <condition>Adult Giant Cell Glioblastoma</condition>
  <condition>Adult Glioblastoma</condition>
  <condition>Adult Gliosarcoma</condition>
  <condition>Adult Oligodendroglioma</condition>
  <condition>Recurrent Adult Brain Tumor</condition>
  <arm_group>
    <arm_group_label>Arm I (trebananib and bevacizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and trebananib IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (bevacizumab and placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive bevacizumab as in arm I and placebo IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross over to arm I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>trebananib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (trebananib and bevacizumab)</arm_group_label>
    <other_name>AMG 386</other_name>
    <other_name>AMG386</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo administration</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II (bevacizumab and placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (trebananib and bevacizumab)</arm_group_label>
    <arm_group_label>Arm II (bevacizumab and placebo)</arm_group_label>
    <other_name>anti-VEGF humanized monoclonal antibody</other_name>
    <other_name>anti-VEGF monoclonal antibody</other_name>
    <other_name>Avastin</other_name>
    <other_name>rhuMAb VEGF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (trebananib and bevacizumab)</arm_group_label>
    <arm_group_label>Arm II (bevacizumab and placebo)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (trebananib and bevacizumab)</arm_group_label>
    <arm_group_label>Arm II (bevacizumab and placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven diagnosis of glioblastoma or variants (gliosarcoma,
             glioblastoma with oligodendroglial features, giant cell glioblastoma); patients will
             be eligible if the original histology was a lower-grade glioma and a subsequent
             histological diagnosis of glioblastoma or variants is made

          -  Patients must have shown unequivocal evidence for tumor progression on the previous
             treatment regimen (prior to enrollment on this study) by magnetic resonance imaging
             (MRI) scan of the brain with and without contrast within 14 days prior to
             registration; the dose of steroids must be stable or decreasing for at least 5 days
             prior to the scan

               -  Patients unable to undergo MRI because of non-compatible devices can be
                  enrolled, provided computed tomography (CT) scans are obtained and are of
                  sufficient quality; patients without non-compatible devices may not have CT
                  scans performed to meet this requirement

          -  Patients who have received prior treatment with interstitial brachytherapy,
             stereotactic radiosurgery, or implanted chemotherapy sources, such as wafers of
             polifeprosan 20 with carmustine, must have confirmation of progressive disease within
             14 days prior to registration based upon nuclear imaging, MR spectroscopy, perfusion
             imaging, or histopathology

          -  No more than 2 relapses

          -  No intratumoral hemorrhage or peritumoral hemorrhage, demonstrated by MRI or CT scan,
             Common Terminology Criteria for Adverse Events (CTCAE) v. 4 grade 2 or greater, or
             evidence of significant hemorrhage (regardless of CTCAE, v. 4 grade) defined as &gt; 1
             cm diameter of blood (including postoperative hemorrhage)

          -  Karnofsky performance scale &gt;= 70%

          -  Leukocytes &gt; 3,000/mm^3

          -  Absolute neutrophil count (ANC) &gt;= 1,500/mm^3

          -  Hemoglobin (Hgb) &gt;= 10.0 g/dL (Note: The use of transfusion or other intervention to
             achieve Hgb &gt;= 10.0 g/dL is acceptable)

          -  Platelets &gt;= 100,000/mm^3

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT])
             &lt; 2.5 times institutional upper limit of normal

          -  Bilirubin =&lt; 2.0 mg/dL

          -  Creatinine within normal institutional limits OR creatinine clearance &gt; 60 mL/min
             (per 24-hour urine collection or calculated according to the Cockcroft-Gault formula)

          -  Prothrombin time (PT)/international normalized ratio (INR) =&lt; 1.5

          -  Urinary protein =&lt; 30 mg/dL in urinalysis or =&lt; 1+ on dipstick

          -  Generally well-controlled blood pressure with systolic blood pressure =&lt; 140 mm Hg
             AND diastolic blood pressure =&lt; 90 mm Hg within 5 days prior to registration; the use
             of anti-hypertensive medications to control hypertension is permitted

          -  Women of childbearing potential must have a negative serum beta (β)-human chorionic
             gonadotropin (HCG) pregnancy test within 14 days prior to registration

          -  Women of childbearing potential and male patients who are sexually active must
             practice adequate contraception during therapy and for 180 days (6 months) afterwards

          -  No prior invasive malignancy (except non-melanomatous skin cancer) unless
             disease-free for a minimum of 1095 days (3 years); (for example, carcinoma in situ of
             the breast, oral cavity, or cervix are all permissible)

          -  No gastrointestinal bleeding or any other hemorrhage/bleeding event CTCAE, v. 4 grade
             3 or greater within 30 days prior to study entry

          -  No severe, active co-morbidity, defined as follows:

               -  Unstable angina and/or congestive heart failure requiring hospitalization within
                  180 days (6 months) prior to registration

               -  Transmural myocardial infarction within 180 days (6 months) prior to
                  registration

               -  History of stroke, cerebral vascular accident (CVA), or transient ischemic
                  attack within 180 days (6 months) prior to registration

               -  Acute bacterial or fungal infection requiring intravenous antibiotics at the
                  time of registration

               -  Chronic obstructive pulmonary disease (COPD) exacerbation or other respiratory
                  illness requiring hospitalization or precluding study therapy at the time of
                  registration

               -  Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects

               -  Known acquired immune-deficiency syndrome (AIDS) based upon current CDC
                  definition; note, however, that human immunodeficiency virus (HIV) testing is
                  not required for entry into this protocol

               -  Known coagulopathy that increases risk of bleeding or a history of clinically
                  significant hemorrhages in the past

               -  History of non-healing wounds or ulcers, or bone fractures within 90 days (3
                  months) prior to registration

          -  No prior allergic reaction to the study drugs involved in this study

          -  No prior systemic cytotoxic chemotherapy within 28 days (42 days for nitrosoureas or
             mitomycin C) prior to registration, or patients who have not returned to baseline or
             =&lt; CTCAE v. 4 grade 2 from adverse events (excluding alopecia) due to agents
             administered more than 28 days prior to registration

          -  Patients who received non-cytotoxic drug therapy must be off treatment for at least
             14 days prior to registration

               -  Prior treatment with anti-vascular endothelial growth factor(VEGF)-targeted
                  agents, AMG 386 therapy, or other molecules that inhibit angiopoietins or Tie2
                  receptor including, but not limited to, XL-820, XL-184, and CVX-060/PF-4856884
                  is not allowed regardless of time frame

          -  No patients who have not yet completed at least 21 days (30 days for prior monoclonal
             antibody therapy) since ending other investigational device or drug trials, or who
             are currently receiving other investigational treatments

          -  No treatment within 30 days prior to enrollment with strong immune modulators
             including, but not limited to, systemic cyclosporine, tacrolimus, sirolimus,
             mycophenolate mofetil, methotrexate, azathioprine, rapamycin, thalidomide,
             lenalidomide, and targeted immune modulators such as abatacept (CTLA-4-Ig),
             adalimumab, alefacept, anakinra, belatacept (LEA29Y), efalizumab, etanercept,
             infliximab, or rituximab

          -  No prior radiotherapy within 90 days (3 months) prior to registration unless there is
             either: a) histopathologic confirmation of recurrent tumor; or b) new enhancement on
             MRI outside of the radiation treatment field

          -  No major surgical procedure (including craniotomy) or significant traumatic injury
             within 28 days prior to registration or those patients who receive a non-central
             nervous system (CNS) minor surgical procedures (e.g., core biopsy or fine-needle
             aspiration) within 3 days prior to registration; there is no waiting period for
             central line placement

          -  Prior therapy with anti-VEGF targeted agents (e.g. bevacizumab, cediranib,
             vandetanib, aflibercept, sunitinib, sorafenib, etc.); prior therapy with thalidomide
             and lenalidomide is allowed as long as treatment has not occurred within 30 days
             prior to enrollment

          -  Prior therapy with thalidomide and lenalidomide is allowed as long as treatment has
             not occurred within 30 days prior to enrollment

          -  No therapeutic anticoagulation with warfarin &lt; 7 days prior to registration

               -  Therapeutic or prophylactic therapy with aspirin, a low-molecular weight
                  heparin, or a Factor Xa inhibitor is acceptable

          -  No history of venous or arterial thromboembolism within 12 months prior to
             registration
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eudocia Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiation Therapy Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Providence Alaska Medical Center</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan C. Delgalvis</last_name>
      <phone>907-261-3109</phone>
    </contact>
    <investigator>
      <last_name>Susan C. Delgalvis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Services Foundation</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David G. Brachman</last_name>
      <phone>800-360-6371</phone>
    </contact>
    <investigator>
      <last_name>David G. Brachman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology-Deer Valley Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David G. Brachman</last_name>
      <phone>800-360-6371</phone>
    </contact>
    <investigator>
      <last_name>David G. Brachman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates-West Orange Grove</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivek S. Kavadi</last_name>
      <phone>281-277-5200</phone>
    </contact>
    <investigator>
      <last_name>Vivek S. Kavadi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Hospital</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sam S. Huang</last_name>
      <phone>714-734-6220</phone>
    </contact>
    <investigator>
      <last_name>Sam S. Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Medical Center At Irvine-Orange Campus</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela A. Bota</last_name>
      <phone>877-827-8839</phone>
      <email>ucstudy@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Daniela A. Bota</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Poudre Valley Radiation Oncology</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua H. Petit</last_name>
      <phone>970-482-3328</phone>
    </contact>
    <investigator>
      <last_name>Joshua H. Petit</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Hospital of Central Connecticut</name>
      <address>
        <city>New Britain</city>
        <state>Connecticut</state>
        <zip>06050</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neal B. Goldberg</last_name>
      <phone>860-224-5660</phone>
    </contact>
    <investigator>
      <last_name>Neal B. Goldberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>William Backus Hospital</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dennis E. Slater</last_name>
      <phone>860-886-8362</phone>
    </contact>
    <investigator>
      <last_name>Dennis E. Slater</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey J. Raizer</last_name>
      <phone>312-695-1301</phone>
      <email>cancer@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey J. Raizer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin K. Nicholas</last_name>
      <phone>773-834-7424</phone>
    </contact>
    <investigator>
      <last_name>Martin K. Nicholas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Menorah Medical Center</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Gaur</last_name>
      <phone>913-948-5588</phone>
      <email>amy.krushelniski@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Rakesh Gaur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kansas City CCOP</name>
      <address>
        <city>Prairie Village</city>
        <state>Kansas</state>
        <zip>66208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Gaur</last_name>
      <phone>913-948-5588</phone>
      <email>amy.krushelniski@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Rakesh Gaur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John L. Villano</last_name>
      <phone>859-257-3379</phone>
    </contact>
    <investigator>
      <last_name>John L. Villano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bronson Methodist Hospital</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymond S. Lord</last_name>
      <phone>269-373-7458</phone>
    </contact>
    <investigator>
      <last_name>Raymond S. Lord</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Borgess Medical Center</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymond S. Lord</last_name>
      <phone>269-373-7458</phone>
    </contact>
    <investigator>
      <last_name>Raymond S. Lord</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Michigan Cancer Center</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymond S. Lord</last_name>
      <phone>269-373-7458</phone>
    </contact>
    <investigator>
      <last_name>Raymond S. Lord</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Singing River Hospital</name>
      <address>
        <city>Pascagoula</city>
        <state>Mississippi</state>
        <zip>39581</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James E. Clarkson</last_name>
      <phone>228-809-5292</phone>
    </contact>
    <investigator>
      <last_name>James E. Clarkson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cape Radiation Oncology</name>
      <address>
        <city>Cape Girardeau</city>
        <state>Missouri</state>
        <zip>63703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tapan Roy</last_name>
      <phone>866-334-2230</phone>
      <email>sfmc@sfmc.net</email>
    </contact>
    <investigator>
      <last_name>Tapan Roy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liberty Radiation Oncology Clinic</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64116</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Gaur</last_name>
      <phone>913-948-5588</phone>
      <email>amy.krushelniski@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Rakesh Gaur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Hospital of Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Gaur</last_name>
      <phone>913-948-5588</phone>
      <email>amy.krushelniski@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Rakesh Gaur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Kansas City Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64116</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Gaur</last_name>
      <phone>913-948-5588</phone>
      <email>amy.krushelniski@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Rakesh Gaur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Gaur</last_name>
      <phone>913-948-5588</phone>
      <email>amy.krushelniski@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Rakesh Gaur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heartland Regional Medical Center</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Gaur</last_name>
      <phone>913-948-5588</phone>
      <email>amy.krushelniski@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Rakesh Gaur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cox Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert L. Carolla</last_name>
      <phone>417-269-4520</phone>
    </contact>
    <investigator>
      <last_name>Robert L. Carolla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ozark Health Ventures LLC dba Cancer Research for The Ozarks Springfield</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65802</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert L. Carolla</last_name>
      <phone>417-269-4520</phone>
    </contact>
    <investigator>
      <last_name>Robert L. Carolla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint John's Hospital</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert L. Carolla</last_name>
      <phone>417-269-4520</phone>
    </contact>
    <investigator>
      <last_name>Robert L. Carolla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Estabrook Cancer Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tien-Shew W. Huang</last_name>
      <phone>402-354-5144</phone>
    </contact>
    <investigator>
      <last_name>Tien-Shew W. Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology PC - Albany</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivek S. Kavadi</last_name>
      <phone>281-277-5200</phone>
    </contact>
    <investigator>
      <last_name>Vivek S. Kavadi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates of Central New York PC</name>
      <address>
        <city>East Syracuse</city>
        <state>New York</state>
        <zip>13057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dennis J. Kotlove</last_name>
      <phone>315-472-7504</phone>
    </contact>
    <investigator>
      <last_name>Dennis J. Kotlove</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mission Hospitals Inc</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher H. Chay</last_name>
      <phone>828-213-4150</phone>
    </contact>
    <investigator>
      <last_name>Christopher H. Chay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutherford Hospital</name>
      <address>
        <city>Rutherfordton</city>
        <state>North Carolina</state>
        <zip>28139</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Akron General Medical Center</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchel L. Fromm</last_name>
      <phone>330-344-6348</phone>
    </contact>
    <investigator>
      <last_name>Mitchel L. Fromm</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Summa Akron City Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles A. Kunos</last_name>
      <phone>800-641-2422</phone>
    </contact>
    <investigator>
      <last_name>Charles A. Kunos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Summa Barberton Hospital</name>
      <address>
        <city>Barberton</city>
        <state>Ohio</state>
        <zip>44203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles A. Kunos</last_name>
      <phone>800-641-2422</phone>
    </contact>
    <investigator>
      <last_name>Charles A. Kunos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin P. Redmond</last_name>
      <phone>513-558-4553</phone>
      <email>uchealthnews@uc.edu</email>
    </contact>
    <investigator>
      <last_name>Kevin P. Redmond</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Robinson Radiation Oncology</name>
      <address>
        <city>Ravenna</city>
        <state>Ohio</state>
        <zip>44266</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchel L. Fromm</last_name>
      <phone>330-344-6348</phone>
    </contact>
    <investigator>
      <last_name>Mitchel L. Fromm</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Pointe</name>
      <address>
        <city>West Chester</city>
        <state>Ohio</state>
        <zip>45069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin P. Redmond</last_name>
      <phone>513-558-4553</phone>
      <email>uchealthnews@uc.edu</email>
    </contact>
    <investigator>
      <last_name>Kevin P. Redmond</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terence S. Herman</last_name>
      <phone>405-271-4272</phone>
      <email>julie-traylor@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Terence S. Herman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Natalie W Bryant Cancer Center</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles E. Stewart</last_name>
      <phone>918-494-2200</phone>
    </contact>
    <investigator>
      <last_name>Charles E. Stewart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Cancer Center</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivek S. Kavadi</last_name>
      <phone>281-277-5200</phone>
    </contact>
    <investigator>
      <last_name>Vivek S. Kavadi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Hospital</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neil D. Belman</last_name>
      <phone>610-954-3582</phone>
      <email>infolink@slhn.org</email>
    </contact>
    <investigator>
      <last_name>Neil D. Belman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lyndon J. Kim</last_name>
      <phone>215-955-6084</phone>
      <email>laura.lefko@umassmed.edu</email>
    </contact>
    <investigator>
      <last_name>Lyndon J. Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reading Hospital and Medical Center</name>
      <address>
        <city>West Reading</city>
        <state>Pennsylvania</state>
        <zip>19612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert Yuen</last_name>
      <phone>610-988-9323</phone>
    </contact>
    <investigator>
      <last_name>Albert Yuen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AnMed Health Cancer Center</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David S. Martoccia</last_name>
      <phone>864-512-1000</phone>
      <email>rballew@anmedhealth.org</email>
    </contact>
    <investigator>
      <last_name>David S. Martoccia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spartanburg Regional Medical Center</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia C. Griffin</last_name>
      <phone>800-486-5941</phone>
    </contact>
    <investigator>
      <last_name>Patricia C. Griffin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Upstate Carolina CCOP</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia C. Griffin</last_name>
      <phone>800-486-5941</phone>
    </contact>
    <investigator>
      <last_name>Patricia C. Griffin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rapid City Regional Hospital</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael J. Swartz</last_name>
      <phone>605-716-3982</phone>
      <email>research@rcrh.org</email>
    </contact>
    <investigator>
      <last_name>Michael J. Swartz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Central Austin Cancer Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivek S. Kavadi</last_name>
      <phone>281-277-5200</phone>
    </contact>
    <investigator>
      <last_name>Vivek S. Kavadi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - South Austin Cancer Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivek S. Kavadi</last_name>
      <phone>281-277-5200</phone>
    </contact>
    <investigator>
      <last_name>Vivek S. Kavadi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Austin Midtown</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivek S. Kavadi</last_name>
      <phone>281-277-5200</phone>
    </contact>
    <investigator>
      <last_name>Vivek S. Kavadi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology PA - Bedford</name>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <zip>76022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivek S. Kavadi</last_name>
      <phone>281-277-5200</phone>
    </contact>
    <investigator>
      <last_name>Vivek S. Kavadi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Klabzuba Cancer Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivek S. Kavadi</last_name>
      <phone>281-277-5200</phone>
    </contact>
    <investigator>
      <last_name>Vivek S. Kavadi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Round Rock Cancer Center</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivek S. Kavadi</last_name>
      <phone>281-277-5200</phone>
    </contact>
    <investigator>
      <last_name>Vivek S. Kavadi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Seton Williamson</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78665</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivek S. Kavadi</last_name>
      <phone>281-277-5200</phone>
    </contact>
    <investigator>
      <last_name>Vivek S. Kavadi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Cancer Center Sugar Land</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivek S. Kavadi</last_name>
      <phone>281-277-5200</phone>
    </contact>
    <investigator>
      <last_name>Vivek S. Kavadi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tyler Cancer Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivek S. Kavadi</last_name>
      <phone>281-277-5200</phone>
    </contact>
    <investigator>
      <last_name>Vivek S. Kavadi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Care Northwest - Spokane South</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivek S. Kavadi</last_name>
      <phone>281-277-5200</phone>
    </contact>
    <investigator>
      <last_name>Vivek S. Kavadi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Care Northwest</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivek S. Kavadi</last_name>
      <phone>281-277-5200</phone>
    </contact>
    <investigator>
      <last_name>Vivek S. Kavadi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H. Ian Robins</last_name>
      <phone>877-405-6866</phone>
    </contact>
    <investigator>
      <last_name>H. Ian Robins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Community Memorial Hospital</name>
      <address>
        <city>Menomonee Falls</city>
        <state>Wisconsin</state>
        <zip>53051</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer M. Connelly</last_name>
      <phone>414-805-4380</phone>
    </contact>
    <investigator>
      <last_name>Jennifer M. Connelly</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Froedtert and the Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer M. Connelly</last_name>
      <phone>414-805-4380</phone>
    </contact>
    <investigator>
      <last_name>Jennifer M. Connelly</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>D N Greenwald Center</name>
      <address>
        <city>Mukwonago</city>
        <state>Wisconsin</state>
        <zip>53149</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oconomowoc Memorial Hospital-ProHealth Care Inc</name>
      <address>
        <city>Oconomowoc</city>
        <state>Wisconsin</state>
        <zip>53066-3896</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wingate F. Clapper</last_name>
      <phone>262-928-7632</phone>
    </contact>
    <investigator>
      <last_name>Wingate F. Clapper</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Waukesha Memorial Hospital</name>
      <address>
        <city>Waukesha</city>
        <state>Wisconsin</state>
        <zip>53188</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wingate F. Clapper</last_name>
      <phone>262-928-7632</phone>
    </contact>
    <investigator>
      <last_name>Wingate F. Clapper</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 1, 2013</lastchanged_date>
  <firstreceived_date>May 30, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
